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Introduction
Primary Sjögren’s syndrome (pSS) is a T cell-
mediated autoimmune disorder characterized by 
lymphocytic infiltrates, destruction of the salivary 
glands, and systemic production of autoantibodies 
against ribonucleoprotein particles (SS-A/Ro and 
SS-B/La).1-3 Finding the subtypes M1, M3 and M4 
submandibular gland mAChRs-specific auto anti-
bodies in a majority of patiens with pSS is an im-
portant advance towards understanding the patho-
genesis of pSS.4-6 However, M3 mAChR is the ma-
jor subtype expressed in the membrane of rat sub-
mandibular gland and also, M3 mAChR pSS IgG 
was more active than M1 and M4 mAChRs pSS 
IgG.7 It is assumed that autoreactive T cells and 
M3 mAChR-specific antibodies may recognize 
auto antigens, triggering autoimmunity in the sali-
vary glands, and leading to clinical symptoms of 
mouth and eye dryness (sicca syndrome).8 These 
data indicate an important role for T and B cell 
interactions in the pathogenesis of salivary gland 
autoimmunity. Profound secretary dysfunction 
may be associated with the capacity of these auto 
antibodies to impair the acetylcholine action on 
mAChRs on aqueous salivary secretion.6 However, 
the mechanism underlying the mAChR-specific 
autoantibody-mediated alteration of the secretion 
of salivary mucins via binding to the M3 mAChR 
remains to be defined. 
ABSTRACT 
Background: Patients with primary Sjögren’s syndrome (pSS) produce functional IgG against choli-
noreceptor of exocrine glands modifying their activity. The aim of the present work was to demon-
strate pSS IgG antibodies (pSS IgG) interacting with M3 muscarinic acetylcholine receptors 
(mAChR) of rats submandibular glands that alter mucin release and production via phospholipase C 
(PLC) and cyclooxigenase-2 (COX-2) pathways.      
Methods: Mucin release and production of prostaglandin E2 (PGE2), and total inositol phosphates 
(InsP) were measured in rat submandibular gland in the presence of pSS IgG auto antibodies.  
Results: The auto antibodies interacting with M3 mAChR decreased mucin release and production 
through stimulation of PLC and COX-2. This stimulation leads to an incremental increase in InsP 
production and in PGE2 generation, inducing signalling through the prostaglandin membrane recep-
tors subtype 2 (EP2). Moreover, the decrease in mucin production had negative correlation with 
PGE2 generation and InsP accumulation.  
Conclusion: IgG in patients with pSS could play an important role in the pathoetiology of dry mouth, 
decreasing the salivary mucin through the production of proinflammatory substances and leading to 
the reduction in the protection of the oral tissues. 
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The acinar cells of the submandibular gland re-
ceive both adrenergic and cholinergic innervations 
that regulate secretory responses such as the release 
of water, electrolytes and proteins. It is accepted that 
the release of high molecular weight mucin is pro-
voked by the stimulation of the β adrenergic recep-
tors in rat submandibular glands9,10 and electrical 
stimulation of chorda tympani and can be induced 
by injection of bethanechol in vivo into a dog sub-
mandibular gland.11 The ability of muscarinic cho-
linergic stimulation to elicit mucin release is de-
pendent on the increase of intracellular calcium ion 
in the cells of  rat submandibular gland; this high-
lights the need of calcium function in receptor-
mediated mucin release.12 The increase in intracellu-
lar calcium in antral mucous cells results in the 
stimulation of cyclooxygenase-1 (COX-1) activity, 
which in turn leads to the prostaglandin E2 (PGE2) 
synthesis and its subsequent release from cells. The 
secreted PGE2 may then enhance the calcium-
regulated mucin exocytosed by antral mucosal 
cells.13 The major goal of the present study was to 
demonstrate that the serum IgG from pSS patients 
interacts with M3 mAChR in rat submandibular 
gland and regulates the release and production of 
mucin, and to determine if this effect is associated 
with the activation of phospholipase C (PLC) and 
cyclooxygenase-2 (COX-2). 
Materials and Methods 
Subjects and serological tests 
Female patients within the range of 35–55 yrs of 
age, free from receiving treatment for 6 months, 
and with 7-15 yr from the time of the diagnosis of 
their illness, were selected from the metropolitan 
area of Buenos Aires (Argentina). The patients in 
the present study were 18 women with primary 
Sjögren’s syndrome (pSS) who presented with dry 
mouth, and 16 healthy women (mean age 45 ± 10 
yr) without any systemic diseases (control group). 
The diagnosis of SS was based on four or more of 
the criteria published elsewhere.14 Biopsy results, 
degree of xerostomia and keratoconjunctivitis 
sicca, and the results of serological tests on the 
different groups were the same as previously re-
ported.15 All participants agreed to participate in 
the study, according to an approved protocol satis-
fying the Ethics Committee requirement of Buenos 
Aires University at the School of Dentistry. The 
studies were conducted according to the tenets of 
the Declaration of Helsinki. 
Purification of human IgG 
Serum IgG fraction from patients with pSS and 
from normal individuals (as control) were isolated 
using protein G affinity chromatography as de-
scribed elsewhere16 Briefly, serum were loaded 
onto the protein G affinity columns (Sigma, St 
Louis, MO, USA). The columns were then equili-
brated with 1 M Tris–HCl, pH 8.0, and the col-
umns were then washed with 10 volumes of the 
same buffer. The IgG fraction was eluted with 100 
mM glycine-HCl, pH 3.0, and immediately was 
neutralized with the corresponding buffer. The 
concentration and purification of IgG were deter-
mined using a radial immunodiffusion assay. 
 
Purification of anti-peptide immunoglobulins by 
affinity chromatography 
The IgG fraction from patients with pSS was inde-
pendently subjected to affinity chromatography 
using the M3 mAChR synthesized peptide (25-mer 
peptide; K-R-T-V-P-D-N-Q-C-FI-Q-F-L-S-N-P-A-
V-T-F-G-T-A-I) covalently linked to an affigel 15 
(Bio-Rad, Richmond, CA, USA). The IgG fraction 
was loaded onto the affinity column equilibrated 
with phosphate-buffered saline (PBS) and the non6 
anti-peptide fraction was first eluted using the 
same buffer. Specific anti-peptide autoantibodies 
were then eluted using 3 M KSCN/1 M NaCl, fol-
lowed by immediate extensive dialysis against 
PBS. The IgG concentrations of both nonanti- pep-
tide immunoglobulins (Igs) and specific anti-
muscarinic receptor peptide Igs (pSS IgG) were 
determined using radial immunodiffusion assays. 
Immunological reactivity against the muscarinic 
receptor peptide was evaluated using an enzyme-
linked immunosorbent assay (ELISA).16 
 
Measurement of mucin secretion 
After removing free connective tissue and fat from 
submandibular glands, they were cut into small 
slices that were incubated in 500 µLof Krebs Ringer 
bicarbonate medium (KRB), pH 7.4, with 5% CO2 
in O2 for 30 min at 37 ºC. When inhibitors were 
used, they were included from the beginning of the 
incubation time and stimuli were added during the 
last 15 min. Mucin production and release into the 
medium were determined using the Alcian Blue 
methodology as described by Hall et al.17 and modi-
fied by Sarosiek et al.18 Mucin release and produc-
tion were expressed as micrograms per milligrams 
of total protein (µg/mg protein). 
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PGE2 assay 
Rat submandibular gland slices (10 mg) were in-
cubated for 60 min in 500 µL of KRB, gassed with 
5% CO2 in O2 at 37ºC. Anti-M3 peptide pSS IgG 
or pilocarpine were added 30 minutes before the 
end of the incubation period and blockers were 
added 30 minutes before the addition of different 
concentrations of anti-M3 peptide pSS IgG or 1 x 
10-7 M pilocarpine. The submandibular gland was 
then homogenized in a 1.5 mL polypropylene mi-
crocentrifuge tube. All applied procedures were 
according to the protocol from the PGE2 Biotrak 
Enzyme Immuno Assay System (ELISA; Amer-
sham Biosciences, Piscataway, NJ, USA). The 
PGE2 results were expressed as picograms per mil-
ligram of total protein (pg/mg protein). 
 
Measurement of total labelled inositol phosphates 
(InsP) 
Rat submandibular gland slices were incubated for 
120 min in 500 µL of KRB gassed with 5% CO2 in 
O2 with 1 µCi [myo-3H] inositol ([3H]MI) (Sp. 
Act. 15 Ci mmol-1) from Dupont/New England 
Nuclear. Litium chloride (LiCI) (10 mM) was 
added for inositol monophosphate accumulation. 
Pilocarpine and pSS IgG were added 30 minutes 
before the end of the incubation period and the 
blockers were added 30 minutes before the addi-
tion of the agonist. Water-soluble InsP were ex-
tracted after 120 min and the results were ex-
pressed as area units per milligram of tissue wet 
weight (area/mg wet weight). 
 
Animals 
Male Wistar rats weighing within the range of 250-
300 g from the Pharmacologic Bioterium (School of 
Dentistry, University of Buenos Aires) were used 
throughout the study. The animals were kept in stan-
dard environmental conditions were fed with a com-
mercial pellet diet and water. For surgical removal of 
submandibular glands, the animals were sacrificed 
using ether. The experimental protocol followed the 
Guide to The Care and Use of Experimental Animals 
(DHEW Publication, NIH 80-23).   
 
Drugs 
Pilocarpine (mAChR agonist), pirenzepine (M1 
mAChR antagonist), 4-DAMP (M3 mAChR an- 
 
tagonist), U-73122 (PLC inhibitor), and calphostin 
(PKC inhibitor) were obtained from Sigma Chemi-
cal Co.; FR-12204 (COX-1 inhibitor), DuP 697 
(COX-2 inhibitor), SC 19220 (EP2 receptor an-
tagonist) and AH 6809 (EP1/EP2 receptor antago-
nist) were from Tocris Cookson (Ellisville, MO, 
USA). Stock solutions were freshly prepared in the 
appropriate buffers. The drugs were diluted in the 
bath to achieve the final concentrations as stated in 
the text. 
 
Statistical analysis 
The unpaired Student‘s t-test was used to deter-
mine statistical significance. Analysis of variance 
(ANOVA) and a post-hoc test (Dunnett’s method 
or Student-Newman-Keuls test) were employed 
when a pair wise multiple comparison procedure 
was necessary. Differences between means were 
considered significant if the P-value was < 0.05. 
Results 
At concentrations ranging from 1 x 10-9 M to 1 x 
10-6 M, pSS-associated IgG induced a concentra-
tion-dependent inhibitory effect on the release 
and production of mucin by the rat submandibular 
gland (Figure 1A, B). Normal IgG did not modify 
either the release or production of mucin (Figure 
1A, B). In contrast, pilocarpine increased mucin 
release (Figure 1A) without modifying its produc-
tion (Figure 1B).  
 The M3 mAChR antagonist 4-DAMP, but not 
the M1 MAChR antagonist, pirenzepine, neutralized 
the effect of pSS IgG (1 x 10-7 M) on both mucin 
release and production (Figure 2A). While the 
stimulatory effect of pilocarpine (1 x 10-7 M) on 
mucine release was abrogated by pirenzepine; 4-
DAMP had no effect (Figure 2B). 
To investigate the possibility that PLC and 
COX-2 activities were involved in the inhibitory 
effect of pSS IgG on mucin release and production, 
the effect of selective inhibitors of PLC (U-73122, 5 
x 10-6 M) and of COX-2 (DuP 697, 5 x 10-6 M) 
was determined. U-73122 and DuP 697 prevented 
the pSS IgG mediated inhibition of mucin release 
and production. Moreover, SC 19220 (1 x 10-8 M), 
an EP1 receptor antagonist, also blocked the pSS 
IgG effects (Figure 3 A, B). 
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Figure 1. Dose-response-curves of pSS IgG (●), normal IgG (■) and pilocarpine (○) on mucin release (A) and mucin pro-
duction (B). Rat salivary glands were incubated with each concentration of the reactant for 30 min and the concentration of 
mucin was assayed as described in the Material and Methods. Values represent the mean ± standard error of the mean 
(SEM) of 18 patients with pSS and 16 normal subjects. All experiments were performed in duplicate. *P < 0.001 vs. Nor-
mal IgG or Pilocarpine. 
 
 
Figure 2. Effect of 1 x 10-7 M pSS IgG (A) and 1 x 10-7 M pilocarpine (B) on mucin release (black column) and mucin 
production (white column) by the rat submandibular gland. The salivary glands were incubated for 30 min in the absence 
(basal) or presence of pSS IgG (alone) or with 1 x 10-6 M 4-DAMP or 1 x 10-6 M pirenzepine. Values are expressed as the 
mean ± SEM of 18 pSS patients in each group. Experiments were performed in duplicate. *P < 0.001 vs. Basal.  
**P < 0.001 vs. pSS IgG alone or pilocarpine alone. 
 
To discern the participation of different second 
messengers in the signal transduction pathways 
triggered after pSS IgG binds and activates M3 
mAChR, the production of PGE2 and InsP were 
measured. This clearly demonstrated that pSS IgG 
(1 x 10-7 M) stimulated the accumulation of InsP 
and generated PGE2 (Figure 3C, D). The inhibi-
tion of PLC by U-73122 and the EP1 receptor 
antagonist SC 19220, abrogated the stimulatory 
action of pSS IgG on InsP accumulation (Figure 
3C). Moreover, the inhibition of PLC (U-73122) 
and COX-2 (DuP 697) diminished the stimulatory 
activity of pSS IgG on PGE2 generation. The 
production of both InsP and PGE2 was blocked 
by the M3 mAChR antagonist 4-DAMP (Figure 
3C, D). 
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Figure 3. Upper panel: Dose-response curve of pSS IgG alone (●) or in the presence of 5 x 10-6 M DuP 697 (■), 5 x 10-6 
M U-73122 (▼), and 1 x 10-8 M SC 19220 (♦) on mucin release (A) and mucin production (B). Values are mean ± SEM of 
12 pSS patients in each group. *P < 0.001 vs. pSS IgG + DuP 697, U-73122 or SC 19220.  Lower panel: (C) Total InsP 
accumulation and (D) PGE2 production  in  rat  submandibular glands in the absence (basal) or  presence of 1 x 10-7 M pSS 
IgG (alone), 1 x 10-7 M pSS IgG + U-73122 or SC 19220  or 4-DAMP. Each bar represents 
the mean ± SEM of 12 pSS patients performed in duplicate. *P < 0.001 vs. pSS IgG + U-73122 or SC 19220 or 4-DAMP. 
C: P < 0.001 vs. pSS IgG + U-73122 or SC 19220 or 4-DAMP. D: P < 0.001 vs. pSS IgG + U-73122 or DuP 697 or SC 
19220 or 4-DAMP.                                                                                                          
 
 
There is a significant negative correlation be-
tween pSS IgG-stimulated production of PGE2 and 
InsP with pSS IgG-mediated inhibition of mucin 
production (Figure 4A, B). These results demon-
strated that the activation of the M3 mAChR by pSS 
IgG inhibited mucin production by stimulating InsP 
accumulation and PGE2 production. 
Table 1 shows comparatively, the pSS IgG in-
hibitory action with pilocarpine stimulatory activity 
on mucin release. The pSS IgG-inhibition of mucin 
release could be prevented by COX-2 (DuP 697) 
and EP1 receptor antagonist (SC 19220) or by in-
hibiting the activities of PLC (U-73122) and PKC 
(calphostin). In contrast, the pilocarpine stimulatory 
activity was abrogated by COX-1 (FR 1220479) and 
EP1/EP2 receptor antagonists (AH 6809). PLC (U-
73122) and PKC (calphostin) inhibitors had no ef-
fect on our system. 
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Figure 4. Negative correlation between the inhibition of mucin production and the stimulation of the production of PGE2 
(A) or accumulation of InsP (B) by the IgG from patients with primary Sjögren’s syndrome. Mucin production was plotted 
as a function of PGE2 and total InsP.   
 
Table 1. Effect of different inhibitors on mucin release by pSS IgG and pilocarpine on submandibular gland 
Additions pSS IgG (1x10-7 M) Pilocarpine (1x10-7 M) 
Basal 30 ± 3 29 ± 2 
Alone 16 ± 1 45 ± 3 
FR 122047 (5x10-8 M) 17 ± 1 32 ± 2 * 
DuP 697 (5x10-8 M) 28 ± 1 * 47 ± 3 
SC 19220 (1x10-5 M) 31 ± 3 * 46 ± 4 
AH 6809 (3x10-5 M) 32 ± 3 * 30 ± 3 * 
U-73122 (1x10-6 M) 26 ± 2 * 44 ± 4 
Calphostin (1x10-8 M) 29 ± 2 * 43 ± 4 
 
Mucin release by affinity purified M3 peptide autoantibodies from patients with primary Sjögren’s syn-
drome (pSS IgG) and pilocarpine. Rat submandibular glands were incubated for 30 minutes in the absence 
(basal) or presence of pSS IgG or pilocarpine alone or with different inhibitors. Pilocarpine or pSS IgG 
were added in the last 10 minutes. Values are expressed in µg mucin/mg protein and are the mean ± SEM 
of 6 experiments in each group. * P < 0.001 vs. pSS IgG or pilocarpine alone. 
 
Discussion 
Autoantibody acting at the level of the post-synaptic 
M3 mAChR of rat submandibular gland have been 
implicated in the autonomic parasympathetic dys-
function in pSS. Mucin secretion from rat subman-
dibular gland is dependent on the parasympathetic 
stimulation.19,20 Sjögren’s syndrome is an autoim-
mune disease which is characterized by the hallmark 
clinical feature of salivary insufficiency associated 
with focal, periductal and perivenular lymphocytic 
infiltrates21; pSS patients express autoantibodies 
against M3 mAChR that, at least in part, are respon-
sible for altering the parasympathetic control of sa-
liva secretion.22,23 The effectiveness of pilocarpine in 
stimulating mucin release may suggest that the 
muscarinic cholinergic system participates in the 
regulation of mucin release from the rat subman-
dibular gland24 and the mucin secretory response to 
the cholinergic agonist was dependent on the M1 
mAChR subtype and a calcium dependent mecha-
nism.25 In contrast to the stimulatory effects of pilo-
carpine, in this study we demonstrated that patients 
with pSS produce functional IgG autoantibodies that 
interact with glandular M3 mAChR, inhibiting 
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mucin release and production. The antibody-
mediated inhibitory effect correlates with the incre-
mental accumulation of InsP and increase in PGE2 
production. This effect highlighted the possibility 
that autoantibodies play an important role in the 
pathogenesis of dry mouth in pSS patients. Fur-
thermore, we even demonstrated the inhibition of 
mucin or the stimulation of InsP and PGE2 by pSS 
IgG, could be abolished by the inhibition of M3 
mAChR, PLC, or COX-2 activities, indicating that 
pSS IgG functions through M3 mAChR-mediated 
signalling in the submandibular gland membranes. 
Under normal conditions, the constitutive isoform of 
COX-1 is in virtually all organs and its products 
help to maintain normal physiological functions 
such as cytoprotection. This is true for the authentic 
agonist, pilocarpine, which acts on M1 mAChR to 
increase mucin release and provoke an increase in 
PGE2 production via the activation of COX-1. In 
contrast, in an inflammatory setting, the inducible 
isoform of the enzyme (COX-2) is produced, result-
ing in the generation of a large amount of pro-
inflammatory PGE2.26 This pro inflammatory agent 
mediates acute and chronic inflammation, immu-
nological alterations and  
cytotoxic tissue damage.26 In the present study, 
we demonstrated that the pro-inflammatory media-
tor, COX-2, and its product, PGE2, are induced by 
pSS-specific autoantibodies. Therefore, the inflam-
matory process described in the glands of pSS pa-
tients might be attributed partly to antibody fixation 
on membranes that, through interaction with M3 
mAChR, triggers PGE2 production via COX-2 acti-
vation.  
An important feature of the differences seen in 
the effect of pSS IgG and pilocarpine is the ability 
to decrease or increase mucin release, respectively. 
This difference could be related to the mAChR and 
PGE2 receptor subtypes they interact with. In pilo-
carpine-stimulated mucin release, the M1 mAChR 
and EP2 receptor subtypes are involved; in pSS 
IgG-decreased mucin release, the M3 mAChR and 
EP1 receptor subtypes are involved. Moreover, the 
activation of M1 mAChR and EP2 receptors in-
creases cAMP and calcium mobilization,27 while the 
activation of M3 mAChR and EP1 receptors de-
creases cAMP and increases PKC activity.27 In addi-
tion, mucin secretion is stimulated by a number of 
agents that elevate cAMP concentration28 and the 
inhibition of mucin secretion is related to a decrease 
in cAMP and PKC activation.24  
Sjögren’s syndrome patients present a marked 
decrease in output per minute of mucin 5B.29 Mucin 
5B is assumed to coat and protect oral tissue.30-32 
The decreased concentration of mucin 5B in the 
saliva of pSS patients could lead to a reduced pro-
tection of oral tissue and increased susceptibility to 
mucosal damage.29 
Conclusion 
Based on our results, we postulated that the agonist-
promoted activation of glandular M3 mAChR initi-
ated by pSS IgG binding and persistent activation 
results in the production of PGE2 and accumulation 
of InsP, leading to inhibition of mucin release and 
production. This inhibition was mediated by IgG 
autoantibodies in pSS patients and could lead to a 
reduction in the protection of oral tissues and in-
creased susceptibility to mucosal damage. More-
over, it may also promote the presence of plaque at 
the level of gingival margin on the tooth leading to 
caries and periodontal problems, which are fre-
quently seen in SS patients. 
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